Physician profile
Vidhya Ramachandran
NPI 1285796177
$5,995.93
in general payments reported to CMS, 2019-2025
25 companies · $720 in 2025
The $720 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $769 · 2021: $1,313 · 2022: $1,037 · 2023: $814 · 2024: $906 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,197.63 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $872.43 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $681.07 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Tris Pharma INC | $672.79 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $516.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $267.23 | 2019-2025 | Bexsero |
| Sobi, INC | $252.05 | 2019-2024 | |
| Pfizer INC. | $246.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $187.02 | 2020-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $173.96 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $154.49 | 2019-2025 | Doc Band |
| Adlon Therapeutics L.P. | $142.46 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $129.44 | 2021-2025 | Qelbree, Qelbree |
| Genentech USA, INC. | $97.32 | 2019-2021 | |
| Sanofi Pasteur INC. | $82.73 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $60.81 | 2019-2025 | Relexxii |
| Cognoa, INC. | $51.45 | 2022 | |
| Dermira, INC. | $45.54 | 2020 | |
| Aytu Biopharma, INC. | $38.11 | 2024 | Karbinal |
| Cipher Pharmaceuticals US LLC | $24.64 | 2025 | Natroba, Spinosad |
| Seqirus USA INC | $24.22 | 2021-2022 | |
| Biomarin Pharmaceutical INC. | $23.97 | 2025 | Voxzogo 1.2mg |
| Avion Pharmaceuticals | $20.58 | 2023 | Methylphenidate Hydrochloride |
| Novartis Pharmaceuticals Corporation | $16.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Ramachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.